• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Res Vet Sci . Detailed epitope mapping of SARS-CoV-2 nucleoprotein reveals specific immunoresponse in cats and dogs housed with COVID-19 patients

tetano

Editor, Senior Moderator
Res Vet Sci


. 2022 Jan 4;143:81-87.
doi: 10.1016/j.rvsc.2021.12.020. Online ahead of print.
Detailed epitope mapping of SARS-CoV-2 nucleoprotein reveals specific immunoresponse in cats and dogs housed with COVID-19 patients


Barbara Colitti[SUP] 1 [/SUP], Francesco Bonfante[SUP] 2 [/SUP], Santina Grazioli[SUP] 3 [/SUP], Laura Anfossi[SUP] 4 [/SUP], Chiara Nogarol[SUP] 5 [/SUP], Daniela Scalas[SUP] 6 [/SUP], Luigi Bertolotti[SUP] 6 [/SUP], Alessio Bortolami[SUP] 2 [/SUP], Matteo Pagliari[SUP] 2 [/SUP], Giulia Pezzoni[SUP] 3 [/SUP], Ana Moreno[SUP] 7 [/SUP], Davide Lelli[SUP] 7 [/SUP], Maria Silvia Gennero[SUP] 8 [/SUP], Alessandro Dondo[SUP] 8 [/SUP], Emiliana Brocchi[SUP] 3 [/SUP], Sergio Rosati[SUP] 6 [/SUP]



Affiliations

Abstract

Since the initial emergence in December 2019, the novel Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has been reported in over 200 countries, representing an unprecedented challenge related to disease control worldwide. In this context, cases of human to animal transmission have been reported, raising concern about the potential role of companion animals in the pandemic and stressing the need for reliable animal testing. In the study, a detailed epitope mapping of SARS-CoV-2 nucleoprotein, using both human and pet sera, allowed the identification of the most antigenic region in the C-terminus domain of the protein, which was used to develop an experimental double antigen-based ELISA. A panel of pre-pandemic sera and sera of animals immunized against (or naturally infected with) related coronaviruses was used to assess assay specificity at 99.5%. Positive sera belonging to animals housed with COVID-19 patients were confirmed with the experimental double-antigen ELISA using Plaque Reduction Neutralization test (PRNT) test as gold standard. The availability of a serological assay that targets a highly specific viral antigen represents a valuable tool for multispecies monitoring of Coronavirus Disease 2019 (COVID-19) infection in susceptible animals.

Keywords: COVID19; Double antigen ELISA; Epitope mapping; SARS-CoV-2; SARS-CoV-2 nucleoprotein.
 
Back
Top Bottom